ENGELL TORGRIM
No ORCID on file
· 60 papers in corpus
· active 2008-2011
Frequent coauthors
- FAIRWAY STEVEN 45
- HENRIKSEN INGRID 45
- GRIGG JULIAN 15
- PETTITT ROGER 15
- WICKMANN CARINA 15
2011
A diagnostic imaging agent useful for positron emission tomography (PET) imaging as well as to improved hardware for producing such imaging agents is described. Fluciclatide (18F) Injection for the imaging of malignant diseases, heart disea…
2011
A diagnostic imaging agent useful for positron emission tomography (PET) imaging as well as to improved hardware for producing such imaging agents is described. Fluciclatide (18F) Injection for the imaging of malignant diseases, heart disea…
2011
A diagnostic imaging agent useful for positron emission tomography (PET) imaging as well as to improved hardware for producing such imaging agents is described. Fluciclatide (18F) Injection for the imaging of malignant diseases, heart disea…
2011
A diagnostic imaging agent useful for positron emission tomography (PET) imaging as well as to improved hardware for producing such imaging agents is described. Fluciclatide (18F) Injection for the imaging of malignant diseases, heart disea…
2011
A diagnostic imaging agent useful for positron emission tomography (PET) imaging as well as to improved hardware for producing such imaging agents is described. Fluciclatide (18F) Injection for the imaging of malignant diseases, heart disea…
2011
A diagnostic imaging agent useful for positron emission tomography (PET) imaging as well as to improved hardware for producing such imaging agents is described. Fluciclatide (18F) Injection for the imaging of malignant diseases, heart disea…
2011
A diagnostic imaging agent useful for positron emission tomography (PET) imaging as well as to improved hardware for producing such imaging agents is described. Fluciclatide (18F) Injection for the imaging of malignant diseases, heart disea…
2011
A diagnostic imaging agent useful for positron emission tomography (PET) imaging as well as to improved hardware for producing such imaging agents is described. Fluciclatide (18F) Injection for the imaging of malignant diseases, heart disea…
2011
A diagnostic imaging agent useful for positron emission tomography (PET) imaging as well as to improved hardware for producing such imaging agents is described. Fluciclatide (18F) Injection for the imaging of malignant diseases, heart disea…
2011
A diagnostic imaging agent useful for positron emission tomography (PET) imaging as well as to improved hardware for producing such imaging agents is described. Fluciclatide (18F) Injection for the imaging of malignant diseases, heart disea…
2011
A diagnostic imaging agent useful for positron emission tomography (PET) imaging as well as to improved hardware for producing such imaging agents is described. Fluciclatide (18F) Injection for the imaging of malignant diseases, heart disea…
2011
A diagnostic imaging agent useful for positron emission tomography (PET) imaging as well as to improved hardware for producing such imaging agents is described. Fluciclatide (18F) Injection for the imaging of malignant diseases, heart disea…
2011
A diagnostic imaging agent useful for positron emission tomography (PET) imaging as well as to improved hardware for producing such imaging agents is described. Fluciclatide (18F) Injection for the imaging of malignant diseases, heart disea…
2011
A diagnostic imaging agent useful for positron emission tomography (PET) imaging as well as to improved hardware for producing such imaging agents is described. Fluciclatide (18F) Injection for the imaging of malignant diseases, heart disea…
2011
A diagnostic imaging agent useful for positron emission tomography (PET) imaging as well as to improved hardware for producing such imaging agents is described. Fluciclatide (18F) Injection for the imaging of malignant diseases, heart disea…
2010
The present invention relates to new radiolabelled peptide-based compounds and their use for diagnostic imaging using positron emission tomography (PET). Such compounds may thus be used for diagnosis or therapy of, for example, malignant di…
2010
The present invention relates to new radiolabelled peptide-based compounds and their use for diagnostic imaging using positron emission tomography (PET). Such compounds may thus be used for diagnosis or therapy of, for example, malignant di…
2010
The present invention relates to new radiolabelled peptide-based compounds and their use for diagnostic imaging using positron emission tomography (PET). Such compounds may thus be used for diagnosis or therapy of, for example, malignant di…
2010
The present invention relates to new radiolabelled peptide-based compounds and their use for diagnostic imaging using positron emission tomography (PET). Such compounds may thus be used for diagnosis or therapy of, for example, malignant di…
2010
The present invention relates to new radiolabelled peptide-based compounds and their use for diagnostic imaging using positron emission tomography (PET). Such compounds may thus be used for diagnosis or therapy of, for example, malignant di…
2010
The present invention relates to new radiolabelled peptide-based compounds and their use for diagnostic imaging using positron emission tomography (PET). Such compounds may thus be used for diagnosis or therapy of, for example, malignant di…
2010
The present invention relates to new radiolabelled peptide-based compounds and their use for diagnostic imaging using positron emission tomography (PET). Such compounds may thus be used for diagnosis or therapy of, for example, malignant di…
2010
The present invention relates to new radiolabelled peptide-based compounds and their use for diagnostic imaging using positron emission tomography (PET). Such compounds may thus be used for diagnosis or therapy of, for example, malignant di…
2010
The present invention relates to new radiolabelled peptide-based compounds and their use for diagnostic imaging using positron emission tomography (PET). Such compounds may thus be used for diagnosis or therapy of, for example, malignant di…
2010
The present invention relates to new radiolabelled peptide-based compounds and their use for diagnostic imaging using positron emission tomography (PET). Such compounds may thus be used for diagnosis or therapy of, for example, malignant di…